Literature DB >> 2167337

Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects.

T B Sculley1, A Apolloni, L Hurren, D J Moss, D A Cooper.   

Abstract

A possible cofactor in human immunodeficiency virus (HIV) infection is the Epstein-Barr virus (EBV), which is divided into two primary types that differ significantly in their transformation efficiency. The B-type EBV cell line is much more difficult to establish than the A-type. The extent of systemic B-type EBV infection was assessed in HIV-positive subjects and controls. Lymphoblastoid cell lines were established from 26 HIV-positive subjects and analyzed for the presence of A- or B-type EBV by Southern analysis and immunoblotting. Some 19% of HIV-positive persons were infected with B-type EBV, 69% with A-type, and 12% with both types. Analysis of the individual strains of EBV harbored by the HIV-positive subjects showed that HIV-induced immunosuppression had not led to increased susceptibility to repeated EBV infections. However, the occurrence of B-type infection in HIV-positive subjects was sixfold higher than that in the general community, indicating that HIV-induced immunodeficiency or HIV itself specifically enhanced the expression of the B-type EBV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167337     DOI: 10.1093/infdis/162.3.642

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.

Authors:  A J Aguirre; E S Robertson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Novel intertypic recombinants of epstein-barr virus in the chinese population.

Authors:  R S Midgley; N W Blake; Q Y Yao; D Croom-Carter; S T Cheung; S F Leung; A T Chan; P J Johnson; D Huang; A B Rickinson; S P Lee
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 3.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

4.  Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia.

Authors:  D M Walling; S N Edmiston; J W Sixbey; M Abdel-Hamid; L Resnick; N Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

5.  Epstein-Barr virus infection in allogeneic marrow grafting: lessons for transplant physicians and virologists.

Authors:  J W Gratama; M A Oosterveer; J Lepoutre; W E Fibbe; O Ringdén; J M Vossen; R Willemze; R L Bolhuis; J J van Rood; I Ernberg
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

Review 6.  Epstein-Barr virus infection at mucosal surfaces: detection of genomic variants with altered pathogenic potential.

Authors:  J W Sixbey; P Shirley
Journal:  Springer Semin Immunopathol       Date:  1991

7.  Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.

Authors:  Q Y Yao; D S Croom-Carter; R J Tierney; G Habeshaw; J T Wilde; F G Hill; C Conlon; A B Rickinson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

8.  Epstein-Barr virus intrastrain recombination in oral hairy leukoplakia.

Authors:  D M Walling; N Raab-Traub
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression.

Authors:  D M Walling; A G Perkins; J Webster-Cyriaque; L Resnick; N Raab-Traub
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Identification of Epstein-Barr virus strain variants in hairy leukoplakia and peripheral blood by use of a heteroduplex tracking assay.

Authors:  Diane Sitki-Green; Rachel H Edwards; Jennifer Webster-Cyriaque; Nancy Raab-Traub
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.